Table 2.
Univariate and multivariate analyses of prognostic factors in the whole tumor sections of HCC (cohort 1, n = 224)
| Variable | TTR | OS | ||
|---|---|---|---|---|
| HR (95% CI) | P | HR (95% CI) | P | |
| Univariate analysis | ||||
| Age, year (≤ 50 vs. > 50) | 1.239 (0.880–1.746) | .220 | 1.415 (0.973–2.059) | .070 |
| Sex (female vs. male) | 1.205 (0.843–1.722) | .306 | 1.230 (0.692–2.188) | .480 |
| HBsAg (negative vs. positive) | 1.173 (0.760–1.808) | .471 | 0.948 (0.606–1.482) | .815 |
| AFP, ng/ml (≤ 20 vs. > 20) | 1.473 (1.041–2.085) | .029 | 1.616 (1.109–2.355) | .013 |
| GGT, U/L (≤ 54 vs. > 54) | 1.512 (1.063–2.150) | .021 | 1.893 (1.280–2.799) | .001 |
| Liver cirrhosis (no vs. yes) | 1.713 (0.986–2.978) | .056 | 1.406 (0.791–2.500) | .246 |
| Tumor size, cm (≤ 5 vs. > 5) | 1.662 (1.186–2.329) | .003 | 2.573 (1.766–3.749) | .000 |
| Tumor number (single vs. multiple) | 1.364 (0.878–2.119) | .168 | 1.145 (0.709–1.850) | .580 |
| Vascular invasion (no vs. yes) | 1.633 (1.160–2.299) | .005 | 1.962 (1.366–2.817) | .000 |
| Tumor encapsulation (complete vs. none) | 1.170 (0.837–1.635) | .357 | 1.392 (0.968–2.001) | .074 |
| Tumor differentiation (I + II vs. III + IV) | 1.695 (1.199–2.398) | .003 | 1.890 (1.313–2.720) | .001 |
| TNM stage (I vs. II III) | 1.687 (1.208–2.357) | .000 | 1.915 (1.338–2.740) | .000 |
| Intra-pDCs (low vs. high) | 1.837 (1.315–2.566) | .000 | 1.803 (1.379–2.358) | .000 |
| Peri-pDCs (low vs. high) | 1.004 (0.720–1.402) | .979 | 1.270 (0.889–1.815) | .190 |
| Non-pDCs (low vs. high) | 1.133 (0.812–1.582) | .462 | 1.002 (0.998–1.007) | .271 |
| Intra-pDCs and IL-17 + cells (both low vs. both high) | 2.242 (1.529–3.288) | .000 | 2.416 (1.596–3.658) | .000 |
| Intra-pDCs and Treg cells (both low vs. both high) | 2.276 (1.525–3.398) | .000 | 2.442 (1.585–3.764) | .000 |
| Intra- pDCs and IL-17 + , and Treg cells (all low vs. all high) | 2.702 (1.615–4.510) | .000 | 3.014 (1.831–4.962) | .000 |
| Multivariate analysis | ||||
| AFP, ng/ml (≤ 20 vs. > 20) | 1.310 (0.921–1.863) | .133 | 1.444 (0.984–2.119) | .060 |
| GGT, U/L (≤ 54 vs. > 54) | 1.449 (0.991–2.118) | .055 | 1.569 (1.027–2.397) | .037 |
| Tumor size, cm (≤ 5 vs. > 5) | 1.313 (0.915–1.883) | .139 | 1.935 (1.291–2.902) | .001 |
| Vascular invasion (no vs. yes) | 1.225 (0.853–1.759) | .272 | 1.395 (0.956–2.035) | .084 |
| Tumor differentiation (I + II vs. III + IV) | 1.561 (1.086–2.243) | .016 | 1.607 (1.104–2.340) | .013 |
| Intra-pDCs (low vs. high) | 1.715 (1.218–2.416) | .002 | 1.654 (1.150–2.378) | .007 |
| Intra-pDCs and IL-17 + cells (both low vs. both high) | 2.075 (1.395–3.087) | .000 | 1.957 (1.274–3.006) | .002 |
| Intra-pDCs and Treg cells (both low vs. both high) | 2.253 (1.494–3.398) | .000 | 2.326 (1.494–3.621) | .000 |
| Intra-pDCs and IL-17 + , and Treg cells (all low vs. all high) | 2.693 (1.677–4.326) | .000 | 2.702 (1.615–4.520) | .000 |
The boldfaced numerals indicate P value < 0.05
Cox proportional hazards regression model
AFP alpha-fetoprotein, GGT gamma glutamyl transferase, TNM tumor-node-metastasis, HR hazard ratio, CI confidential interval